(Q38219801)

31 August 2017

Consensus report from the 6th International forum for liver MRI using gadoxetic acid (English)

1 reference

31 August 2017

1

1 reference

31 August 2017

8

1 reference

Markus Peck-Radosavljevic

31 August 2017

7

object named as

Markus Peck-Radosavljevic

0 references

Jeong Min Lee

5

object named as

Jeong Min Lee

1 reference

31 August 2017

10

Michiie Sakamoto

1 reference

31 August 2017

Hero K Hussain

2

1 reference

31 August 2017

Eduard Jonas

3

1 reference

31 August 2017

Masayuki Kanematsu

4

1 reference

31 August 2017

Elmar M Merkle

6

1 reference

31 August 2017

Jens Ricke

9

1 reference

31 August 2017

8 November 2013

1 reference

Journal of Magnetic Resonance Imaging

31 August 2017

1 reference

31 August 2017

40

1 reference

31 August 2017

3

1 reference

31 August 2017

516-529

1 reference

Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection

31 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

CT- and MRI-based volumetry of resected liver specimen: comparison to intraoperative volume and weight measurements and calculation of conversion factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

"State of the art" in liver resection and living donor liver transplantation: a worldwide survey of 100 liver centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

How much remnant is enough in liver resection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Assessment of liver function for safe hepatic resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Quantitative assessment of hepatic function and its relevance to the liver surgeon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Total and segmental liver volume variations: implications for liver surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Liver function testing with nuclear medicine techniques is coming of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Segmental liver hyperintensity in malignant biliary obstruction on diffusion weighted MRI: associated MRI findings and relationship with serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Primovist, Eovist: what to expect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

The value of gadoxetate disodium-enhanced MR imaging for predicting posthepatectomy liver failure after major hepatic resection: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Assessment of liver function in primary biliary cirrhosis using Gd-EOB-DTPA-enhanced liver MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Feasibility of randomized controlled trials in liver surgery using surgery-related mortality or morbidity as endpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Contrast agents for MR imaging of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Appearances of colorectal hepatic metastases at diffusion-weighted MRI compared with histopathology: initial observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Diffusion weighted imaging in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Detection of liver metastases using gadoxetic-enhanced dynamic and 10- and 20-minute delayed phase MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatoce

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

High resolution navigated three-dimensional T₁-weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 Tesla.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadolinium ethoxybenzyl diethylenetriamine pentaacetic Acid-enhanced magnetic resonance imaging findings of borderline lesions at high risk for progression to hypervascular classic hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Double-dose gadoxetic Acid-enhanced magnetic resonance imaging in patients with chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi--gadoxetic acid-enhanced MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Hyperintense lesions on gadoxetate disodium-enhanced hepatobiliary phase imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Early hepatocellular carcinoma as an entity with a high rate of surgical cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Hypovascular hepatic nodule showing hypointensity in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease: prediction of malignant transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadoxetic acid-enhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable tumor of hepatocellular carcinomas treated with image-guided tumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

"Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadoxetate disodium-enhanced MR imaging: differentiation between early-enhancing non-tumorous lesions and hypervascular hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Comparison of gadoxetic acid-enhanced MRI and superparamagnetic iron oxide-enhanced MRI for the detection of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Comparison between areas with Gd-EOB-DTPA uptake and without in hepatocellular carcinomas on Gd-EOB-DTPA-enhanced hepatobiliary-phase MR imaging: pathological correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadoxetic acid-enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Magnetic resonance elastography as a predictor of insufficient liver enhancement on gadoxetic acid-enhanced hepatocyte-phase magnetic resonance imaging in patients with type C hepatitis and Child-Pugh class A disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Imaging Characteristics of Hepatocellular Carcinoma Using the Hepatobiliary Contrast Agent Gd-EOB-DTPA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Hypervascular hepatocellular carcinomas: detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

21 January 2018

Identifiers

DOI

10.1002/JMRI.24419

1 reference

31 August 2017

1 reference